iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. We show 21 historical shares outstanding datapoints in our ITOS shares outstanding history coverage, used to compute ITOS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ITOS market cap history over the course of time is important for investors
interested in comparing ITOS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ITOS versus a peer is one thing; comparing
ITOS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ITOS can fluctuate over the course of history.
With this page we aim to empower investors researching ITOS by allowing them to research the ITOS market cap history. |
Free ITOS Email Alerts:
Video: The Importance of Market Cap
